MX2025006291A - Metodos de tratamiento de trastornos neurologicos - Google Patents

Metodos de tratamiento de trastornos neurologicos

Info

Publication number
MX2025006291A
MX2025006291A MX2025006291A MX2025006291A MX2025006291A MX 2025006291 A MX2025006291 A MX 2025006291A MX 2025006291 A MX2025006291 A MX 2025006291A MX 2025006291 A MX2025006291 A MX 2025006291A MX 2025006291 A MX2025006291 A MX 2025006291A
Authority
MX
Mexico
Prior art keywords
neurological disorders
methods
treating neurological
treating
compositions
Prior art date
Application number
MX2025006291A
Other languages
English (en)
Inventor
Paul Dransfield
Dilinie Fernando
James Harvey
Brian Sparling
John Stellwagen
Zhihua Ma
Anne-Marie Beausoleil
Ryan Hudson
Original Assignee
Neumora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neumora Therapeutics Inc filed Critical Neumora Therapeutics Inc
Publication of MX2025006291A publication Critical patent/MX2025006291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a compuestos de Fórmula (I), (Ver Fórmula (I)). y sales farmacéuticamente aceptables de los mismos, en donde la variable es como se describe en la presente, y composiciones y usos de la misma para tratar trastornos neurológicos.
MX2025006291A 2022-12-02 2025-05-29 Metodos de tratamiento de trastornos neurologicos MX2025006291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263429760P 2022-12-02 2022-12-02
PCT/US2023/082070 WO2024119067A1 (en) 2022-12-02 2023-12-01 Methods of treating neurological disorders

Publications (1)

Publication Number Publication Date
MX2025006291A true MX2025006291A (es) 2025-09-02

Family

ID=89618965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025006291A MX2025006291A (es) 2022-12-02 2025-05-29 Metodos de tratamiento de trastornos neurologicos

Country Status (9)

Country Link
US (3) US11993580B1 (es)
EP (1) EP4626878A1 (es)
JP (1) JP2025541771A (es)
KR (1) KR20250110929A (es)
CN (1) CN120379982A (es)
AU (1) AU2023406476A1 (es)
IL (1) IL321201A (es)
MX (1) MX2025006291A (es)
WO (1) WO2024119067A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1271116B (de) 1965-05-04 1968-06-27 Bayer Ag Verfahren zur Herstellung von 4-Hydroxypyrimidinen
HU203736B (en) 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
CA2274093C (en) 1996-12-05 2006-11-07 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
CA2275601A1 (en) 1996-12-20 1998-07-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridazines
JP2001524544A (ja) 1997-12-04 2001-12-04 アムジエン・インコーポレーテツド 置換ピリミジノン類の製造方法
AU5428700A (en) 1999-06-25 2001-01-31 Sumitomo Chemical Company, Limited Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
CA2384783A1 (en) 1999-09-14 2001-03-22 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2002015902A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
US7335776B2 (en) 2001-03-14 2008-02-26 Ono Pharmaceutical Co., Ltd. Remedies for depression containing EP1 antagonist as the active ingredient
AU2002247402A1 (en) 2001-03-23 2002-10-08 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
AU2003214110A1 (en) 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
AU2003216591A1 (en) 2002-04-10 2003-10-20 Orichid Chemicals And Pharmaceuticals Limited Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
MXPA04011470A (es) 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
DE10238725A1 (de) 2002-08-23 2004-03-04 Bayer Cropscience Ag Substituierte Heterocyclypyrimidine
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP1613606A4 (en) 2003-04-07 2008-12-03 Nps Pharma Inc PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
DE10328810B4 (de) 2003-06-20 2005-10-20 Infineon Technologies Ag Syntheseverfahren für eine Verbindung zur Bildung einer selbstorganisierenden Monolage, Verbindung zur Bildung einer selbstorganisierenden Monolage und eine Schichtstruktur für ein Halbleiterbauelement
US20050020646A1 (en) 2003-06-25 2005-01-27 Pfizer Inc. Treatment of BPH
AU2004267096B2 (en) 2003-08-20 2008-10-02 Amgen Inc. Substituted pyrimdinone derivatives and methods of use
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7029834B2 (en) 2003-10-15 2006-04-18 Eastman Kodak Company Thermally developable imaging materials having backside stabilizers
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
MY143245A (en) 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
JP2008500951A (ja) 2004-05-31 2008-01-17 田辺三菱製薬株式会社 二環化合物
JP2006028056A (ja) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd ピリミジン誘導体及びこれを含む有害生物防除剤
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
WO2006058535A2 (de) 2004-11-30 2006-06-08 Technische Universität Dresden N-heterozyklische carbenkomplexe des platins und des palladiums, deren herstellung und verwendung zur partiellen oxidation von kohlenwasserstoffen
WO2006066070A2 (en) 2004-12-17 2006-06-22 Nps Pharmaceuticals, Inc. Prodrug constructs of pyrimidinone compounds as calcilytics
EP1910338B1 (en) 2005-07-14 2010-08-25 Irm, Llc Heterotetracyclic compounds as tpo mimetics
JP2007145819A (ja) 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd 医薬組成物
JP2007176933A (ja) 2005-11-29 2007-07-12 Tanabe Seiyaku Co Ltd 医薬組成物
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
AU2009208712B2 (en) 2008-02-01 2013-03-14 Orchid Chemicals & Pharmaceuticals Limited Novel heterocycles
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
KR20100125316A (ko) 2008-03-26 2010-11-30 다이이찌 산쿄 가부시키가이샤 하이드록시퀴녹살린카르복사마이드 유도체
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
KR100958641B1 (ko) 2008-08-18 2010-05-20 삼성모바일디스플레이주식회사 광효율 개선층을 구비한 유기 발광 소자
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
JP2011088888A (ja) 2009-09-24 2011-05-06 Daiichi Sankyo Co Ltd ヒドロキシキノキサリンカルボキサミド誘導体を含有する医薬組成物
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2012004217A1 (en) 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
WO2012068335A2 (en) 2010-11-18 2012-05-24 Dalhousie University Novel catalysts
EP2543372A1 (en) 2011-07-08 2013-01-09 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for the treatment of liver cancer
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
WO2013007792A1 (en) 2011-07-14 2013-01-17 Thurgauische Stiftung Für Wissenschaft Und Forschung Novel th2 polarizing compounds
BR112014004832A2 (pt) 2011-08-29 2017-04-04 Ptc Therapeutics Inc compostos antibacterianos e métodos para uso
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
WO2013096093A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
BR112014027133A2 (pt) 2012-05-09 2017-06-27 Basf Se compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal.
CN105073111A (zh) 2012-10-11 2015-11-18 默沙东公司 用作gpr120激动剂的取代的螺哌啶基化合物
CN102875479B (zh) 2012-10-24 2015-06-10 南京化工职业技术学院 喹唑啉二酮衍生物及其制备方法、其药物组合物及用途
AU2014319373B2 (en) 2013-09-11 2018-05-24 Syngenta Participations Ag Heterocyclic amide compound and herbicide
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2015069752A1 (en) 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
US10292976B2 (en) 2014-01-09 2019-05-21 Riken Anti-malarial agent
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
WO2015191382A1 (en) 2014-06-11 2015-12-17 E. I. Du Pont De Nemours And Company Fungicidal tetrazolinones
KR101887213B1 (ko) 2014-08-12 2018-08-09 삼성에스디아이 주식회사 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
KR101829749B1 (ko) 2014-10-31 2018-02-19 삼성에스디아이 주식회사 유기 광전자 소자용 화합물, 유기 광전자 소자용 조성물, 유기 광전자 소자 및 표시 장치
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
CN109689642B (zh) 2016-07-14 2022-04-12 百时美施贵宝公司 经单环杂芳基取代的化合物
CN109803660A (zh) 2016-08-10 2019-05-24 细胞基因公司 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗
US11993590B2 (en) 2016-12-04 2024-05-28 712 North Inc. Pyranone compounds useful to modulate OMA1 protease
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
US20200016136A1 (en) 2017-01-03 2020-01-16 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CN106928204B (zh) 2017-02-13 2020-03-03 牡丹江医学院 一种哌嗪类衍生物、其制备方法及其用途
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
CN110964037B (zh) 2018-09-29 2023-03-28 沈阳中化农药化工研发有限公司 含嘧啶并环类化合物及其制备方法和用途
AR117990A1 (es) 2019-02-06 2021-09-08 Syngenta Crop Protection Ag Compuestos herbicidas
WO2020198710A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
WO2020257653A1 (en) 2019-06-20 2020-12-24 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
KR102811543B1 (ko) 2019-10-16 2025-05-23 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물
KR102399037B1 (ko) 2020-01-06 2022-05-17 성균관대학교산학협력단 아민화된 아진의 신규한 제조방법
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
KR102929256B1 (ko) 2020-08-11 2026-02-23 주식회사 엘지화학 화합물 및 이를 포함하는 유기 발광 소자
WO2022076627A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN112375088B (zh) 2020-11-30 2022-05-20 吉林奥来德光电材料股份有限公司 一种螺类含氮有机发光化合物、其制备方法及应用
CN112480113B (zh) 2020-11-30 2022-03-08 吉林奥来德光电材料股份有限公司 一种螺类含氮有机发光化合物、其制备方法及应用
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Also Published As

Publication number Publication date
KR20250110929A (ko) 2025-07-21
US20260062401A1 (en) 2026-03-05
US20240246928A1 (en) 2024-07-25
US11993580B1 (en) 2024-05-28
IL321201A (en) 2025-07-01
WO2024119067A1 (en) 2024-06-06
EP4626878A1 (en) 2025-10-08
CN120379982A (zh) 2025-07-25
US20240294492A1 (en) 2024-09-05
JP2025541771A (ja) 2025-12-23
AU2023406476A1 (en) 2025-06-05
US12371414B2 (en) 2025-07-29

Similar Documents

Publication Publication Date Title
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
CR20250329A (es) Compuestos tricíclicos para el tratamiento del cáncer
GEAP202416135A (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2023013245A (es) Rescorcinoles, metodos para su fabricacion, y usos de los mismos.
EP4365179A3 (en) Novel rapamycin derivatives
WO2019173082A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2024013838A (es) Compuestos y usos de estos
PH12022551523A1 (en) Cyclic compounds and methods of using same
MX2025008327A (es) Composiciones y metodos para el tratamiento de trastornos del snc
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2023006063A (es) Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central.
MX2024013215A (es) Compuestos para inhibir kif18a
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
PH12021552375A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2025000635A (es) Compuestos cíclicos y métodos de utilización de estos
PH12012501589A1 (en) Macrocycles as factor xia inhibitors
PH12021552377A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
ZA202400823B (en) Inhibitors of transglutaminases
GEAP202516737A (en) Compounds for treating cancer
ZA202400821B (en) Inhibitors of transglutaminases
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b